Mind over matter - prospects for the CNS market
This article was originally published in Scrip
Executive Summary
The recent failure of Newron's experimental analgesic ralfinamide to show any significant therapeutic benefit over placebo should remind us, if a reminder were necessary, that developing drugs to treat conditions affecting the central nervous system (CNS) is fraught with difficulties. Some of this uncertainty arises as a result of our incomplete understanding of many CNS disorders, from Alzheimer's disease to epilepsy, and from anxiety to psychosis.